Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q9HAE3

UPID:
CLXN_HUMAN

ALTERNATIVE NAMES:
EF-hand calcium-binding domain-containing protein 1

ALTERNATIVE UPACC:
Q9HAE3; B4DSB4; E7EVN7

BACKGROUND:
Calaxin, also known as EF-hand calcium-binding domain-containing protein 1, is integral to the outer dynein arm-docking complex, facilitating the binding of outer dynein arms to microtubules. It plays a vital role in the regulation of ciliary and flagellar motility, crucial for the proper determination of body laterality. The protein's function in the assembly of dynein arms and their docking complex underscores its importance in cellular motility and structural integrity.

THERAPEUTIC SIGNIFICANCE:
The exploration of Calaxin's function offers a promising avenue for the development of novel therapeutic approaches. Given its critical role in regulating ciliary and flagellar motility, targeting Calaxin could provide innovative treatments for conditions associated with motility defects.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.